Literature DB >> 28413188

Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Concentration and Risk of Cardiovascular Events - Systematic Review and Meta-Analysis of Prospective Studies.

Yunjun Xiao1, Chaoqiong Peng1, Wei Huang1, Jinzhou Zhang1, Yang Gao2, Jean H Kim3, Eng-Kiong Yeoh3, Xuefen Su3,4.   

Abstract

BACKGROUND: Previous studies have not found a consistent association between circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) and the risk of cardiovascular events. The aim of this meta-analysis was to evaluate this association in prospective studies.Methods and 
Results: A systematic search of prospective studies published through October 2016 was carried out in order to identify studies that met pre-specified inclusion criteria. After independent data extraction, summary relative risks were calculated using random-effects models. On meta-analysis of 6 cohort and 1 nested case-control study, circulating PCSK9 concentration as a continuous variable was not significantly associated with the risk of cardiovascular events (overall RR, 1.12; 95% CI: 0.98-1.29; P=0.09), with significant heterogeneity (I2=55.1%, Pheterogeneity=0.038). The highest but not middle categories of circulating PCSK9 was significantly associated with the risk of cardiovascular events. On subgroup analysis of study design, mean age at baseline, sample size, follow-up time, and pre-existing disease, there was no significant association between PCSK9 and cardiovascular events. Sensitivity analysis with various exclusion and inclusion criteria did not materially change the results.
CONCLUSIONS: Circulating PCSK9 concentration as a continuous variable was not significantly associated with the risk of cardiovascular events. More well-designed studies are needed to clarify the role of PCSK9 in cardiovascular risk.

Entities:  

Keywords:  Cardiovascular; Event; Meta-analysis; Proprotein convertase subtilisin/kexin type 9 (PCSK9); Prospective study

Mesh:

Substances:

Year:  2017        PMID: 28413188     DOI: 10.1253/circj.CJ-16-1142

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  6 in total

Review 1.  PCSK9: From Basic Science Discoveries to Clinical Trials.

Authors:  Michael D Shapiro; Hagai Tavori; Sergio Fazio
Journal:  Circ Res       Date:  2018-05-11       Impact factor: 17.367

2.  High circulating proprotein convertase subtilisin/Kexin type 9 concentration associates with cardiovascular risk: A meta-analysis of cohort studies.

Authors:  Chengfeng Qiu; Quan Zhou; Xiaohui Li; Zhen Zhang; Pingyu Zeng; Zeng Cao; Bingjie Pan; Xiaogang Li; Alex F Chen
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

Review 3.  Lipid Lowering Therapy and Circulating PCSK9 Concentration.

Authors:  Tsuyoshi Nozue
Journal:  J Atheroscler Thromb       Date:  2017-08-14       Impact factor: 4.928

4.  Methotrexate Decreases the Level of PCSK9-A Novel Indicator of the Risk of Proatherogenic Lipid Profile in Psoriasis. The Preliminary Data.

Authors:  Julita Anna Krahel; Anna Baran; Tomasz W Kamiński; Magdalena Maciaszek; Iwona Flisiak
Journal:  J Clin Med       Date:  2020-03-26       Impact factor: 4.241

5.  Association Between Circulating Proprotein Convertase Subtilisin/Kexin Type 9 and Major Adverse Cardiovascular Events, Stroke, and All-Cause Mortality: Systemic Review and Meta-Analysis.

Authors:  Yimo Zhou; Weiqi Chen; Meng Lu; Yongjun Wang
Journal:  Front Cardiovasc Med       Date:  2021-03-02

6.  Evolocumab, a PCSK9-Monoclonal Antibody, Rapidly Reverses Coronary Artery Endothelial Dysfunction in People Living With HIV and People With Dyslipidemia.

Authors:  Thorsten M Leucker; Gary Gerstenblith; Michael Schär; Todd T Brown; Steven R Jones; Yohannes Afework; Robert G Weiss; Allison G Hays
Journal:  J Am Heart Assoc       Date:  2020-07-17       Impact factor: 5.501

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.